Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

661. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy

A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy Article Text Clinical prediction guide A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy Statistics from Altmetric.com No Altmetric

Evidence-Based Medicine (Requires free registration)2008

662. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial

Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial 18332267 2008 03 25 2008 10 22 2014 11 20 1524-4539 117 12 2008 Mar 25 Circulation Circulation Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. 1518-25 10.1161/CIRCULATIONAHA.107.723866 The present study assessed the efficacy and safety of vernakalant hydrochloride (RSD1235), a novel compound (...) , for the conversion of atrial fibrillation (AF). Patients were randomized in a 2:1 ratio to receive vernakalant or placebo and were stratified by AF duration of 3 hours to 7 days (short duration) and 8 to 45 days (long duration). A first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes, followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if AF was not terminated. The primary end point was conversion of AF to sinus rhythm for at least 1 minute within 90 minutes

EvidenceUpdates2008

663. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. OBJECTIVE: To assess the association between atrial fibrillation and flutter and use of bisphosphonates for osteoporosis among women. DESIGN: Population based case-control study, using medical databases from Denmark. SETTING: Northern Denmark. PARTICIPANTS: 13 586 patients with atrial fibrillation and flutter and 68 054 population controls, all with complete hospital (...) and prescription history. MAIN OUTCOME MEASURE: Adjusted relative risk of atrial fibrillation and flutter. RESULTS: 435 cases (3.2%) and 1958 population controls (2.9%) were current users of bisphosphonates for osteoporosis. Etidronate and alendronate were used with almost the same frequency among cases and controls. The adjusted relative risk of current use of bisphosphonates compared with non-use was 0.95 (95% confidence interval 0.84 to 1.07). New users had a relative risk of 0.75 (95% confidence interval

BMJ2008 Full Text: Link to full Text with Trip Pro

664. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation

Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation 18294564 2008 02 25 2008 03 06 2016 10 19 1558-3597 51 8 2008 Feb 26 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. 810-5 10.1016/j.jacc.2007.09.065 We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF (...) )-related thromboembolism in a large community-based cohort. Risk schemes can help target anticoagulant therapy for patients at highest risk for AF-related thromboembolism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention in Atrial Fibrillation, CHADS(2) (Congestive heart failure, Hypertension, Age >or= 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

665. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data

Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data 17483128 2008 01 15 2008 01 30 2013 11 21 1468-201X 94 2 2008 Feb Heart (British Cardiac Society) Heart Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. 191-6 In heart failure, digitalis increases exercise capacity and reduces morbidity, but has no effect on survival. This raises the suspicion that the inotropic benefits of digitalis may be counteracted (...) by serious adverse effects. Patients with atrial fibrillation (AF) were studied to clarify this. In the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation (SPORTIF) III and V studies, 7329 patients with AF at moderate-to-high risk were randomised to preventive treatment of thromboembolism, either with warfarin or the oral direct thrombin inhibitor ximelagatran. The survival of users and non-users of digitalis was investigated. At baseline, 53.4% of the study population used

EvidenceUpdates2008

666. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review

Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review Noheria A, Kumar A, Wylie J V, Josephson M E CRD summary The authors concluded that the use of circumferential pulmonary vein ablation for atrial fibrillation may increase atrial tachyarrhythmia recurrence-free (...) survival at 12 months compared with anti-arrhythmic drug therapy, but larger studies are required. Other than the limited search the review was well-conducted. The authors’ cautious conclusions reflect the limitations of the evidence and are likely to be reliable. Authors' objectives To compare circumferential pulmonary vein ablation (CPVA) with anti-arrhythmic drug therapy (ADT) for the treatment of atrial fibrillation (AF). Searching PubMed, EMBASE and the Cochrane Controlled Trials Register were

DARE.2008

667. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials

Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D CRD summary This poorly reported review concluded that statin use can significantly reduce (...) the risk of incidence or recurrence of atrial fibrillation in patients in sinus rhythm undergoing cardiac surgery or following acute coronary syndrome. This conclusion reflects the results of the review, but the limited searches and lack of methodological reporting may limit the reliability of the findings. Authors' objectives To assess the effectiveness of statins in preventing atrial fibrillation (AF). Searching MEDLINE was searched from January 1980 to June 2007; the search terms were reported

DARE.2008

668. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery

Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Zebis LR, Christensen TD, Kristiansen IS, Hjortdal VE Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of using postoperative amiodarone for the prevention of atrial fibrillation in patients undergoing a coronary artery bypass graft for stable angina. The authors concluded that the prophylactic use of amiodarone reduced the risk of atrial fibrillation

NHS Economic Evaluation Database.2008

669. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis

Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis Andersen L V, Vestergaard P, Deichgraeber P, Lindholt J S, Mortensen L S, Frost L CRD summary This review concluded that warfarin reduced the risk (...) of stroke and systemic embolism in patients with non-valvular atrial fibrillation, but increased the risk of major bleeding. There were several limitations with the included trials and the reporting in the review, such as no validity assessment and potential bias, so the authors' conclusions should be interpreted with caution. Authors' objectives To assess the efficacy of warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation. Searching MEDLINE, EMBASE

DARE.2008

670. Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation?

Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Murtuza B, Pepper J R, Stanbridge R D, Darzi A, Athanasiou T CRD summary The authors discovered there may be no difference in rates of postoperative atrial fibrillation after minimal (...) access aortic valve replacement compared to conventional aortic valve replacement and recommended further research. Although the conclusions appeared to be supported by the evidence, the limited literature search and lack of information about study quality mean that some caution in interpretation may be required. Authors' objectives To compare the incidence of postoperative atrial fibrillation associated with minimal access aortic valve replacement and conventional aortic valve replacement. Searching

DARE.2008

671. Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation

Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) BlueCross BlueShield Association. Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation. Chicago IL: BlueCross BlueShield Association (BCBS). TEC Assessment 23(11). 2008 Authors' objectives The objective of this Assessment is to determine whether radiofrequency catheter ablation improves health outcomes when used as a treatment for patients with atrial fibrillation. Three indications for radiofrequency catheter ablation are addressed: 1) patients with recent onset

Health Technology Assessment (HTA) Database.2008

672. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton GK, Tanajewski L, Turner D, Price A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. Southampton

Health Technology Assessment (HTA) Database.2008

674. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y CRD summary This review concluded that in atrial fibrillation patients (...) patients with atrial fibrillation receiving oral anticoagulation (vitamin-K antagonists). Searching MEDLINE, EMBASE and the Cochrane Library were searched from January 1990 to January 2008 for articles published in any language. Search terms were reported. Reference lists of retrieved trials and review articles were scanned. Study selection Randomised controlled trials (RCTs), prospective cohorts and retrospective studies of vitamin K antagonists in unselected adults with atrial fibrillation were

DARE.2008

675. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus (...) on atrial fibrillation Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY CRD summary The authors concluded that the optimal antithrombotic regime for atrial fibrillation in patients undergoing percutaneous coronary interventions with stenting was undefined. They recommended triple therapy (warfarin, aspirin, clopidogrel) as the most effective regime, but with an increased risk of bleeding. This recommendation may be unreliable

DARE.2008

676. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies

Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP CRD summary This review concluded there were benefits to treating heart failure with cardiac resynchronisation (...) ; patients with atrial fibrillation had greater improvement in ejection fraction, but smaller improvements in functional outcomes than those in sinus rhythm. Mortality was similar in both groups. Given some problems with the review and less reliable data from observational studies, these conclusions should be treated with caution. Authors' objectives To determine the effects of cardiac resynchronisation therapy in patients with atrial fibrillation compared with those in sinus rhythm. Searching MEDLINE

DARE.2008

677. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies

Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies Liu T, Li L, Korantzopoulos P, Liu E, Li G CRD summary (...) The authors concluded that statins may be effective in preventing atrial fibrillation especially in postoperative patients, but there was insufficient evidence to recommend statins solely to prevent atrial fibrillation. Further research was required. This was generally a well-conducted review and the authors' cautious conclusions reflected the paucity of good-quality evidence. Authors' objectives To examine the association between statins and the development of atrial fibrillation. Searching MEDLINE

DARE.2008

678. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials

Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials Kanji S, Stewart R, Fergusson D A, McIntyre L, Turgeon A F, Hebert P C CRD summary (...) The authors found insufficient evidence to make recommendations about standard treatment of noncardiac critically ill patients with new-onset atrial fibrillation. Despite some concerns about the risk of language and publication bias, this was generally a well-conducted review and the authors’ conclusions were likely to be reliable. Authors' objectives To evaluate the efficacy of pharmacological rhythm control treatments for new-onset atrial fibrillation in noncardiac critically ill adult patients

DARE.2008

679. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Shepherd J (...) , Jones J, Frampton G K, Tanajewski L, Turner D, Price A CRD summary RCTs directly comparing intravenous magnesium sulphate with sotalol were not identified, but the authors did conclude that intravenous magnesium is effective in preventing atrial fibrillation in patients undergoing coronary artery bypass graft when compared to controls. This was a well conducted piece of research, which considered limitations with the included studies. The authors' conclusions are likely to be reliable. Authors

DARE.2008

680. Curative ablation for atrial fibrillation: a systematic review

Curative ablation for atrial fibrillation: a systematic review Curative ablation for atrial fibrillation: a systematic review Curative ablation for atrial fibrillation: a systematic review Gjesdal K, Vist G E, Bugge E, Rossvoll O, Johansen M, Norderhaug I, Ohm O J CRD summary This systematic review concluded that catheter ablation was more effective than drug therapy for atrial fibrillation, but that data on adverse effects was sparse. The review appeared to have been reasonably well conducted (...) , although poor reporting limited the assessment of some sources of bias. The authors' conclusions reflected the evidence presented, but the low quality of the included studies limited the reliability of the conclusions. Authors' objectives To assess the effectiveness of catheter ablation for atrial fibrillation. Searching MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, The Cochrane Library, meta Register of Controlled Trials and relevant websites were searched to May 2007. Study

DARE.2008